Analysts Are Revising Their Forecasts Teva Pharmaceutical Industries (NYSE:TEVA)

0
148

Earnings results for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is expected* to report earnings on 11/05/2020 before market open. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.56. The reported EPS for the same quarter last year was $0.56.

Teva Pharmaceutical Industries last released its earnings results on August 5th, 2020. The reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.94 billion. Its quarterly revenue was down 7.3% compared to the same quarter last year. Teva Pharmaceutical Industries has generated $2.31 earnings per share over the last year and currently has a price-to-earnings ratio of 4.0. Teva Pharmaceutical Industries has confirmed that its next quarterly earnings report will be published on Thursday, November 5th, 2020.

Analyst Opinion on Teva Pharmaceutical Industries (NYSE:TEVA)

17 Wall Street analysts have issued ratings and price targets for Teva Pharmaceutical Industries in the last 12 months. Their average twelve-month price target is $12.07, predicting that the stock has a possible upside of 31.07%. The high price target for TEVA is $16.00 and the low price target for TEVA is $8.00. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of “Hold.”

Teva Pharmaceutical Industries has received a consensus rating of Hold. The company’s average rating score is 2.12, and is based on 5 buy ratings, 9 hold ratings, and 3 sell ratings. According to analysts’ consensus price target of $12.07, Teva Pharmaceutical Industries has a forecasted upside of 31.1% from its current price of $9.21. Teva Pharmaceutical Industries has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries does not currently pay a dividend. Teva Pharmaceutical Industries does not have a long track record of dividend growth.

Insiders buying/selling: Teva Pharmaceutical Industries (NYSE:TEVA)

In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,024.00 in company stock. Only 0.56% of the stock of Teva Pharmaceutical Industries is held by insiders. 52.87% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Teva Pharmaceutical Industries (NYSE:TEVA

Earnings for Teva Pharmaceutical Industries are expected to grow by 5.00% in the coming year, from $2.40 to $2.52 per share. The P/E ratio of Teva Pharmaceutical Industries is 3.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 19.27. The P/E ratio of Teva Pharmaceutical Industries is 3.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.60. Teva Pharmaceutical Industries has a PEG Ratio of 0.70. PEG Ratios below 1 indicate that a company could be undervalued. Teva Pharmaceutical Industries has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

More latest stories: here